Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8351 to 8400 of 8907 results

  1. Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy (TA381)

    This guidance has been updated and replaced by NICE technology appraisal guidance 908.

    Withdrawn guidance

  2. Ruxolitinib for treating polycythaemia vera (terminated appraisal) (TA356)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA921.

    Withdrawn guidance

  3. The clinical effectiveness and cost effectiveness of etanercept and infliximab for rheumatoid arthritis and juvenile poly-articular idiopathic arthritis (TA36)

    This guidance has been replaced by NICE technology appraisal guidance 130 and NICE technology appraisal guidance 195.

    Withdrawn guidance

  4. Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer (TA360)

    This guidance has been updated and replaced by NICE technology appraisal guidance 476.

    Withdrawn guidance

  5. Simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C (terminated appraisal) (TA361)

    The appraisal has been withdrawn because Janssen withdrew their marketing authorisation on 1 May 2018. The availability of direct-acting antiviral combination treatments for hepatitis C has reduced the use of simeprevir, so the company has decided to discontinue it.

    Withdrawn guidance

  6. Daclatasvir for treating chronic hepatitis C (TA364)

    This guidance has been withdrawn because Bristol-Myers Squibb has discontinued daclatasvir (Daklinza).

    Withdrawn guidance

  7. The clinical effectiveness and cost effectiveness of irinotecan, oxaliplatin and raltitrexed for colorectal cancer (TA33)

    This guidance has been replaced by NICE technology appraisal guidance 93 [Replaced by NICE guideline CG131].

    Withdrawn guidance

  8. Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C (TA331)

    The guidance has been withdrawn because Janssen withdrew their marketing authorisation on 1 May 2018. The availability of direct-acting antiviral combination treatments for hepatitis C has reduced the use of simeprevir, so the company has decided to discontinue it.

    Withdrawn guidance

  9. Sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer (TA332)

    This appraisal has been withdrawn. This is because the marketing authorisation for sipuleucel-T was withdrawn on 19 May 2015.

    Withdrawn guidance

  10. Apremilast for treating moderate to severe plaque psoriasis (TA368)

    Withdrawn guidance

  11. The clinical effectiveness and cost effectiveness of rituximab for follicular lymphoma (TA37)

    This guidance has been updated and replaced by NICE technology appraisal guidance 137.

    Withdrawn guidance

  12. Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane (TA371)

    This guidance has been updated and replaced by NICE technology appraisal guidance 458.

    Withdrawn guidance

  13. Apremilast for treating active psoriatic arthritis (TA372)

    This guidance has been updated and replaced by NICE technology appraisal guidance 433.

    Withdrawn guidance

  14. Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA376)

    This guidance has been updated and replaced by NICE technology appraisal guidance 412.

    Withdrawn guidance

  15. The clinical effectiveness and cost effectiveness of bupropion (Zyban) and Nicotine Replacement Therapy for smoking cessation (TA39)

    This guidance has been updated and replaced by NICE guideline PH10. 

    Withdrawn guidance

  16. Implantable cardioverter defibrillators for arrhythmias (TA95)

    This guidance has been updated and replaced by NICE technology appraisal guidance 314.

    Withdrawn guidance

  17. Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (TA963)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1064

    Withdrawn guidance

  18. Computerised cognitive behaviour therapy for depression and anxiety (TA97)

    The guidance was withdrawn in July 2018 to allow OCFighter to be considered for an improving access to psychological therapies assessment briefing. If OCFighter is not selected, it may be considered for a medtech innovation briefing.

    Withdrawn guidance

  19. Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (TA885)

    This guidance has been updated and replaced by NICE technology appraisal guidance 939.

    Withdrawn guidance

  20. The use of autologous chondrocyte implantation for the treatment of cartilage defects in the knee joints (TA89)

    This guidance has been updated and replaced by NICE technology appraisal guidance 477. 

    Withdrawn guidance

  21. Diabetes (type 2) - rosiglitazone (TA9)

    This guidance has been replaced by NICE technology appraisal guidance 63.

    Withdrawn guidance

  22. Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events (TA90)

    This guideline has been updated and replaced by NICE technology appraisal 210.

    Withdrawn guidance

  23. SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal) (TA834)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1045.

    Withdrawn guidance

  24. Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids (terminated appraisal) (TA839)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1054.

    Withdrawn guidance

  25. Drotrecogin alfa (activated) for severe sepsis (TA84)

    November 2011 On 25 October 2011, Eli Lilly and Company announced the withdrawal of its Xigris (drotrecogin alfa [activated]) product in all markets following results of the PROWESS–SHOCK study, which showed the study did not meet the primary endpoint of a statistically significant reduction in 28-day all-cause mortality in patients with septic shock. The company is working with regulatory agencies on this withdrawal, and is in the process of notifying healthcare professionals and clinical trial investigators. As a result of this, NICE has withdrawn its guidance on the use of drotrecogin alfa (activated) for severe sepsis.

    Withdrawn guidance

  26. Immunosuppressive therapy for renal transplantation in adults (TA85)

    This guidance has been updated and replaced by NICE technology appraisal guidance 481.

    Withdrawn guidance

  27. Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy (TA855)

    NICE has withdrawn this guidance. Takeda will stop marketing mobocertinib (Exkivity) and its marketing authorisation has been withdrawn. Healthcare professionals should discuss alternative treatment options with people currently having mobocertinib.  

    Withdrawn guidance

  28. Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal) (TA869)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1015.

    Withdrawn guidance

  29. The clinical effectiveness and cost effectiveness of technologies for the secondary prevention of osteoporotic fractures in postmenopausal women (TA87)

    This guidance has been updated and replaced NICE technology appraisal guidance 161.

    Withdrawn guidance

  30. Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed (TA93)

    This guidance has been updated and replaced by NICE guideline NG151. The recommendations on raltitrexed have been withdrawn because its use is established clinical practice.

    Withdrawn guidance

  31. Targeted-release budesonide for treating primary IgA nephropathy (TA937)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1128.

    Withdrawn guidance

  32. Statins for the prevention of cardiovascular events (TA94)

    This guidance has been updated and replaced by NICE guideline CG181.

    Withdrawn guidance

  33. Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (TA909)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1103.

    Withdrawn guidance

  34. Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer (TA91)

    This guidance has been updated and replaced by NICE technology appraisal guidance 389.

    Withdrawn guidance

  35. Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA823)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1071.

    Withdrawn guidance

  36. Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA831)

    This guidance has been updated and replaced by NICE technology appraisal guidance 887.

    Withdrawn guidance

  37. Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA711)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA815.

    Withdrawn guidance

  38. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents (TA98)

    This guidance has been updated and replaced by NICE guideline NG87.

    Withdrawn guidance

  39. Voxelotor for treating haemolytic anaemia caused by sickle cell disease (TA981)

    NICE has withdrawn this guidance. Pfizer has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that the product is being withdrawn. The recall notification is being shared with all healthcare professionals. No new people will start taking voxelotor in the UK. Healthcare professionals should discuss alternative treatment options with people currently having voxelotor.

    Withdrawn guidance

  40. Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (TA985)

    This guidance has been withdrawn because the simple discount patient access scheme for QuiremSpheres has been withdrawn.

    Withdrawn guidance

  41. Immunosuppressive therapy for renal transplantation in children and adolescents (TA99)

    This guidance has been updated and replaced by NICE technology appraisal guidance 482.

    Withdrawn guidance

  42. Lutonix drug-coated balloon for peripheral arterial disease (MIB72)

    NICE withdrew this medtech innovation briefing in October 2019 after the MHRA withdrew support for this type of technology being used in intermittent claudication for arterial disease.

    Withdrawn advice

  43. Ultroid 2.0 for internal haemorrhoids (MIB75)

    This medtech innovation briefing is temporarily unavailable, please contact mibs@nice.org.uk for further information.

    Withdrawn advice

  44. VitalPAC for assessing vital signs of patients in hospital (MIB79)

    This advice has been updated and replaced by NICE medtech innovation briefing 205.

    Withdrawn advice

  45. Zio Service for detecting cardiac arrhythmias (MIB101)

    This advice has been updated and replaced by NICE healthtech guidance 562.

    Withdrawn advice

  46. IQoro for stroke-related dysphagia (MIB175)

    September 2025: This medtech innovation briefing (MIB) has been withdrawn. This is because the evidence for the technology has changed since the MIB was published. NICE no longer produces or maintains MIBs on behalf of NHS England.

    Withdrawn advice

  47. IQoro for hiatus hernia (MIB176)

    September 2025: This medtech innovation briefing (MIB) has been withdrawn. This is because the evidence for the technology has changed since the MIB was published. NICE no longer produces or maintains MIBs on behalf of NHS England.

    Withdrawn advice

  48. PredictSure-IBD for inflammatory bowel disease prognosis (MIB178)

    This medtech innovation briefing has been updated and replaced by NICE medtech innovation briefing 313.

    Withdrawn advice

  49. Mepilex Border dressings for preventing pressure ulcers (MIB124)

    This advice has been updated and replaced by NICE medical technologies guidance 40.

    Withdrawn advice

  50. Promonitor for monitoring response to biologics in rheumatoid arthritis (MIB126)

    This advice has been replaced by NICE HealthTech guidance 521.

    Withdrawn advice